Meeting
2024 ASCO Annual Meeting
A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.
Presenter
Nikhil I. Khushalani, MD
H. Lee Moffitt Cancer Center and Research Institute
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT06246916
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS9611)
DOI
10.1200/JCO.2024.42.16_suppl.TPS9611
Abstract #
TPS9611
Poster Bd #
389a
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.
Speaker: Ana Baramidze
Videos & Slides
ASCO Plenary Series
Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)
Speaker: Georgina V. Long, MD, PhD, FRACP
Videos & Slides
ASCO Plenary Series
Discussion of Abstract 360385: Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047).
Speaker: Adil Daud, MD
Videos & Slides
2022 ASCO Annual Meeting
Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.
Speaker: Reinhard Dummer, MD